Your session is about to expire
← Back to Search
UBX1325 for Age-Related Macular Degeneration
Study Summary
This trial will test if it is safe to give patients with wet AMD another injection of UBX1325.
- Age-Related Macular Degeneration (AMD)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 26 Patients • NCT03022292Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are enrolled in this clinical experiment?
"To successfully complete this clinical trial, 46 individuals meeting the requirements for inclusion must be recruited. Participants can find participating medical sites at Wilmer Eye Institute located in Baltimore, MD and Retina-Vitreous Associates Medical Group situated in Beverly Hills, IL."
To what extent could UBX1325 be detrimental to those taking it?
"Our team at Power has rated UBX1325's safety as a 2; this assessment is based on the lack of evidence supporting efficacy, though there are some encouraging signs related to its security."
Are there any openings for prospective participants in this clinical experiment?
"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical study, which was initially published March 2nd 2022, is actively seeking participants. In total there are 46 slots available across 26 different sites."
How widespread is the access to this research endeavor?
"Wilmer Eye Institute at John Hopkins University in Baltimore, Retina-Vitreous Associates Medical Group in Beverly Hills, and Salehi Retina Institute are amongst the 26 participating sites for this medical trial. Additionally, there are numerous other locations recruiting patients as well."
Share this study with friends
Copy Link
Messenger